The DUSP22 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population generated from the HeLa human cervical adenocarcinoma epithelial cell line (Homo sapiens). This product offers a heterogeneous loss-of-function model for studying dual-specificity phosphatase 22 (DUSP22) in a widely utilized epithelial background. The polyclonal format ensures a diverse genetic pool, minimizing clonal bias and providing reproducible population-level phenotypic readouts.
HeLa cells, derived from a cervical adenocarcinoma, are HPV18-positive and have been immortalized for decades as a standard cell biology model. Their epithelial origin makes them particularly relevant for investigating signaling pathways involved in cervical carcinogenesis. The well-characterized growth characteristics and extensive molecular toolbox available for HeLa cells facilitate detailed mechanistic studies of gene function.
DUSP22 encodes a dual-specificity phosphatase that selectively dephosphorylates and inhibits the stress-activated MAP kinases JNK1, JNK2, p38??, and p38??. It is recruited to active signaling complexes containing upstream kinases TAK1, ASK1, and MKK7, where it dampens signal transduction by removing phosphate groups from key activation-loop residues. This activity is triggered by stimuli such as T-cell receptor engagement, PMA/ionomycin treatment, and oxidative stress. By suppressing JNK/p38 signaling, DUSP22 limits the transcriptional activity of AP-1 and NF-??B, leading to reduced expression of cytokines like IL-2. Consequently, DUSP22 knockout leads to sustained hyperactivation of these MAPK pathways, promoting pro-inflammatory gene expression and increased cell survival signaling.
Although HeLa cells lack the full T-cell receptor machinery, they retain intact JNK, p38, and NF-??B modules, making DUSP22 knockout a focused system for investigating MAPK phosphatase activity independent of T-cell inputs. The resultant hyperactive JNK/p38 signaling can be used to probe DUSP22’s tumor-suppressive functions in cervical adenocarcinoma, especially given the HPV-positive status of the cells. This model may help elucidate how DUSP22 loss contributes to HPV-mediated oncogenesis and innate immune dysregulation.
Researchers can employ this knockout model for numerous applications, including mechanistic studies of MAPK pathway regulation, substrate identification for DUSP22, and cancer signaling research. Representative assays include Western blotting for phospho-JNK and phospho-p38, AP-1/NF-??B luciferase reporter assays, co-immunoprecipitation of DUSP22 with JNK or TAK1, and phospho-kinase arrays to profile global phosphorylation changes. Additional readouts such as flow cytometry for proliferation and apoptosis, RNA-seq transcriptome profiling, and in vitro phosphatase assays are compatible with this model. These polyclonal knockout cells are valuable for functional genomics screens and drug target validation in cervical and immune-related cancers. For further information, please contact Ascent Research.
